Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 1 client • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Clark+Elbing LLP - Moderna handles 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. This specific workload is part of the firm's broader career history of 8984 applications. The 5 pending office actions represent the firm's current prosecution tasks for this client. The firm's experience in Biotechnology & Pharmaceuticals is built on a foundation of 8984 career applications.
The firm's resolved allowance rate is 67.87 percent, which is calculated from their 8984 career applications. This 67.87 percent rate serves as an indicator of the firm's performance in securing patent allowances. An average of 3.89 office actions per allowance is required to reach a grant. For practitioners, this 3.89 average provides a standard for the expected number of responses to the patent office. The 5 pending office actions are managed alongside this 67.87 percent allowance rate and 3.89 office action average. These data points offer a comprehensive view of the firm's prosecution history and current activity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 27.0% | +27.0% |
| CARR, DEBORAH D | 1 | 81.8% | +2.7% |
| LEONARD, ARTHUR S | 1 | 50.8% | +50.2% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | SHIN, DANA H | — |
| 18551704 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | CARR, DEBORAH D | — |
| 18161598 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | SHIN, DANA H | — |
| 18177455 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | LEONARD, ARTHUR S | — |
| 18161598 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | VANHORN, ABIGAIL LOUISE | — |
| 17277829 | STEROL ANALOGS AND USES THEREOF | MCDOWELL, BRIAN E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Moderna | 5 |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1631 | 1 |
| 1636 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | Modernatx, Inc. | SHIN, DANA H | §112DP | Non-Final OA | — | Pending | Feb 29, 2024 | |
| 18551704 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | Modernatx, Inc. | CARR, DEBORAH D | 1691 | §102§103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18177455 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | Modernatx, Inc. | LEONARD, ARTHUR S | 1631 | §103§112DPOther | Non-Final OA | — | Pending | Mar 02, 2023 |
| 18161598 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | Modema Tx, Inc. | VANHORN, ABIGAIL LOUISE | 1636 | §103§112Other | Non-Final OA | — | Pending | Jan 30, 2023 |
| 17277829 | STEROL ANALOGS AND USES THEREOF | Modernatx, Inc. | MCDOWELL, BRIAN E | 1624 | Other | Non-Final OA | — | Pending | Mar 19, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial